Treating atopic dermatitis
at its source
Epsilon is a chimeric protein that both removes IgE already bound to inflammatory cells and blocks circulating IgE from binding - the only therapy addressing the root-cause of allergic response.
>50% of dogs don’t respond to current therapies
Skin allergies are the #1 medical condition requiring veterinary attention in dogs. Atopic dermatitis results in itching, fur loss, dry, cracking skin, and lesions - significantly impacting quality of life.
Current therapies have fundamental limitations
Allergen-Specific
Immunotherapy
Only targets specific allergens and requires injections every 3-4 weeks for 12+ months. More than 40% of dogs don’t respond to treatment.
Anti-Inflammatories
(e.g., Steroids)
Provides short term relief, but doesn’t treat the root cause of allergic response. Significant negative effects with long-term use limit their therapeutic window.
Other Therapies
Cytopoint (anti-IL-31) and Apoquel (JAK inhibitor) provide itch relief but don’t treat the root cause IgE-driven inflammation or reduce allergic sensitization.
All Therapies
All current therapies require daily to monthly dosing at the vet or at home, impacting quality of life for dogs and their owners.
The Science
A dual-action mechanism - the first of its kind
ACTION 1
Removes bound IgE from cells
The FcεRIα component displaces IgE already bound to the high-affinity receptor on mast cells and dendritic cells — stripping sensitized cells of their trigger and reversing ongoing allergic response.
ACTION 2
Blocks circulating IgE from binding
The anti-IgE scFv sequesters circulating IgE, preventing fresh sensitization of inflammatory cells. This addresses the root cause of future allergic cascades — not just current symptoms.
DIFFERENTIATION
Complimentary to Cytopoint & Apoquel
Epsilon operates upstream of both IL-31 and JAK signaling - enabling a standalone or add-on role for dogs with incomplete response to existing therapies. Partners can expand their product portfolio without cannibalizing existing revenue.
HUMAN OPTIONALITY
Platform applications in human allergy
The same chimeric architecture directly addresses human IgE-mediated disease including atopic dermatitis, asthma, and food allergy - a pipeline opportunity that substantially expands total addressable value beyond veterinary use.
DEVELOPMENT HISTORY
A decade of rigorous development
|
2016
Completed laboratory development and began 1st clinical trial
|
2017
Demonstrated clinical effectiveness in 5 symptomatic dogs
|
2021
Demonstrated safety in high-dose safety trial in 6 non-allergic dogs
|
2024
Patent granted in US and Japan, pending in Europe
|
2025
Demonstrated longitudinal effectivity in 3 symptomatic dogs
CLINICAL EVIDENCE
Three completed trials - all positive outcomes
BioEpsilon has conducted a structured early-stage clinical program demonstrating efficacy, safety, and durability in target canine subjects.
Efficacy - 5 symptomatic dogs (2017)
1
First-in-dog trial in 5 client-owned dogs with chronic atopic dermatitis. Epsilon removed bound IgE from mast cells and blocked circulating IgE in all tested dogs. 100% response rate. Average protection period: 95 days. One dog (Dog A) remained symptom-free for >225 days after ceasing all other treatments.
Safety - 6 non-allergic dogs (2021)
2
6 non-allergic dogs received 3 injections over 4 weeks (3 at standard dose 3 mg/kg, 3 at double dose 6 mg/kg). Full hematology, serum chemistry, and clinical monitoring for 89 days post-final injection. No serious adverse reactions observed at any timepoint in either cohort.
Longitudinal efficacy - 3 symptomatic dogs (2025)
3
Extended treatment monitoring in 3 dogs with confirmed CAD. Epsilon produced durable protection dramatically exceeding current standard of care. Results compared directly to each dog's baseline flare interval on current treatment.
Note: 2 of 14 dogs across all trials vomited after initial injection; managed with dose reduction on subsequent injections. No serious adverse events in any trial. Full data packages available under NDA.
OWNER FEEDBACK
From the dogs - and the people who know them best
Client-owned dogs participated in all efficacy trials. Their owners provided feedback after treatment.
“His scratching and licking decreased, his skin improved quickly, and he was able to rest more comfortably… Ollie went from a dog who started avoiding his daily walks to one who was able to enjoy them again.”
— Owner of Ollie -Trial 3, Dog 1 · 105-day protection period
“Once he'd had the full series of injections, Beans' allergies were better controlled than they had ever been on Apoquel. Cytopoint injections did not work for him - this did.”
— Owner of Beans - Trial 3, Dog 2 · 102-day protection period
COMMERCIAL POSITIONING
Standalone or complementary -
your choice
Epsilon provides a standalone treatment pathway or a complementary option for dogs with incomplete response to existing therapies. Partners can expand their CAD portfolio without disrupting existing product revenue.
Dogs unresponsive to Cytopoint or Apoquel
Standalone - first-line alternative with distinct upstream mechanism.
Dogs with partial response to current therapies
Complementary add-on - Epsilon targets IgE mechanics while existing therapy manages downstream inflammation.
License the Epsilon product family
BioEpsilon is offering licenses to two products with complementary commercial roles in the CAD diagnostic and treatment pathway.
Treatment of canine atopic dermatitis.
Available in the US, EU, Japan
Epsilon-c
Measurement of high-affinity receptor; measures circulating Epsilon levels.
Available in the US
High-Affinity Binder
COMMERCIAL OFFERING
Get in Touch
Seeking strategic licensing partnerships. We are in active discussions with animal health and human pharmaceutical companies. Request a confidential briefing to receive our full clinical data package.
